Top Markets
Coin of the day
Destiny Pharma plc Destiny Pharma plc

Destiny Pharma plc

DEST
Rank in Stocks #41142
Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in... Destiny Pharma plc is a biotechnology company based in Brighton, UK, founded in 1996, specializing in the identification, progression, and market introduction of pharmaceutical solutions for infectious diseases. The company's clinical pipeline includes NTCD-M3, currently in Phase III trials to prevent recurring Clostridioides difficile infections. Its XF-73 program features XF-73 Nasal, undergoing Phase II development for the prevention of post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I for treating bacterial skin infections resistant to antibiotics. Additionally, Destiny Pharma's preclinical efforts involve SPOR-COV, a biotherapeutic product aimed at preventing COVID-19 and other viral respiratory diseases, and XF Drugs Biofilm, targeting antibiotic-resistant biofilm and bacterial aggregate infections. The company is also investigating further applications of its XF drugs for respiratory, oral mucosa, and ocular infections. Destiny Pharma maintains strategic alliances with various organizations, including China Medical System Holdings Limited, SporeGen Limited, the University of Southampton, Aston University, the University of Sheffield, Cardiff University, and Tianjin Medical University.
Share Price
$0.04082105
Last synced: 2024-08-12
Market Cap
$39.09K
Change (1 day)
-19.83%
Change (1 year)
0.00%
Country
GB
Trade Destiny Pharma plc (DEST)

Category

P/E ratio for Destiny Pharma plc (DEST)
P/E ratio as of August 2026 TTM: -0.48
According to Destiny Pharma plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.48. At the end of 2022 the company had a P/E ratio of -5.77.
P/E ratio history for Destiny Pharma plc from 2013 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.48 -95.71%
2023 -11.22 94.28%
2022 -5.77 -50.95%
2021 -11.77 105.60%
2020 -5.73 43.10%
2019 -4.00 -23.47%
2018 -5.23 -67.89%
2017 -16.28 -77.40%
2016 -72.04 -17.08%
2015 -86.89 68.93%
2014 -51.43 -47.63%
2013 -98.22 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
28.05 -5,933.65%
US
31.14 -6,577.58%
NL
- -
CH
- -
KR
19.30 -4,113.87%
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.